使用长效胰岛素类似物或 NPH 胰岛素的 2 型糖尿病患者在基础胰岛素治疗方案中的直接医疗成本。
Direct healthcare costs of patients with type 2 diabetes using long-acting insulin analogues or NPH insulin in a basal insulin-only regimen.
机构信息
COWI A/S, Parallelvej 2, 2800 Kongens Lyngby, Denmark.
出版信息
Prim Care Diabetes. 2010 Oct;4(3):165-72. doi: 10.1016/j.pcd.2010.04.004. Epub 2010 May 10.
AIMS
To compare direct healthcare costs incurred by patients with type 2 diabetes in Denmark prescribed long-acting insulin analogues (LAIA) or intermediate-acting human insulin (NPH) in a basal-only regimen.
METHODS
Demographic and socio-economic patient characteristics, hospital utilisation data, primary care visits, specialist physician visits and prescription data were extracted from registers covering the Danish population. Patients receiving basal insulin were identified during a 1-year inclusion period (2005) and allocated to a LAIA (n=303) or NPH group (n=8523). LAIA patients were then matched with NPH patients using propensity scores based on observable covariates. Annual direct healthcare costs were determined during a <2-year analysis period (2005-2006).
RESULTS
Direct healthcare costs, including prescription costs, were equivalent between groups. However, while most cost items were similar between groups, ambulatory visit costs were significantly lower in LAIA-treated patients (p=0.03), whereas insulin pharmacy costs were significantly lower in NPH-treated patients (p<0.001).
CONCLUSION
There was no difference in direct healthcare costs between patients using LAIAs or NPH insulin.
目的
比较丹麦接受长效胰岛素类似物（LAIA）或中效人胰岛素（NPH）基础胰岛素方案治疗的 2 型糖尿病患者的直接医疗成本。
方法
从覆盖丹麦人群的登记处提取人口统计学和社会经济患者特征、医院利用数据、初级保健就诊、专科医生就诊和处方数据。在 1 年的纳入期（2005 年）内，接受基础胰岛素治疗的患者被确定，并分配到 LAIA（n=303）或 NPH 组（n=8523）。然后，根据可观察到的协变量使用倾向评分对 LAIA 患者与 NPH 患者进行匹配。在<2 年的分析期（2005-2006 年）内确定年度直接医疗成本。
结果
包括处方费用在内的直接医疗成本在两组之间相当。然而，虽然大多数费用项目在两组之间相似，但 LAIA 治疗患者的门诊就诊费用显著较低（p=0.03），而 NPH 治疗患者的胰岛素药房费用显著较低（p<0.001）。
结论
使用 LAIA 或 NPH 胰岛素的患者之间直接医疗成本没有差异。
Zotero 插件